​177Lu-NRT6020 / Chengdu New Radiomedicine Technology - LARVOL DELTA

Exploring Synergy between 177Lu-Labeled FAP Cyclic Peptide and Oncolytic Virus in the Therapeutic Landscape of Triple-Negative Breast Cancer (SNMMI 2025) - "[68Ga]Ga/[177Lu]Lu-FAP-NRT6020 demonstrated high radiochemical purity, stability, and superior tumor retention compared to FAPI-04 and FAP-2286. PET imaging revealed higher SUVmax and T/N ratios for [68Ga]Ga-FAP-NRT6020. Therapeutic studies showed dose-dependent efficacy in inhibiting tumor growth and extending survival with minimal toxicity at optimal doses."

IO biomarker • Oncolytic virus • Breast Cancer • Infectious Disease • Oncology • Solid Tumor • Triple Negative Breast Cancer • CAFs • CD8 • FAP • IL12A